Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit W-sh/W-sh mice. by Piconese, S. et al.
Exacerbated experimental autoimmune
encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice
Silvia Piconese1,*, Massimo Costanza2,*, Silvia Musio2, Claudio Tripodo3, Pietro L Poliani4, Giorgia Gri5,
Alessia Burocchi1, Paola Pittoni1, Andrea Gorzanelli1, Mario P Colombo1 and Rosetta Pedotti2
Mast cell (MC)-deficient c-Kit mutant KitW/W-v mice are protected against experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis, suggesting a detrimental role for MCs in this disease. To further investigate
the role of MCs in EAE, we took advantage of a recently characterized model of MC deficiency, KitW-sh/W-sh. Surprisingly,
we observed that myelin oligodendrocyte glycoprotein (MOG)35–55-induced chronic EAE was exacerbated in Kit
W-sh/W-sh
compared with Kitþ /þ mice. KitW-sh/W-sh mice showed more inflammatory foci in the central nervous system (CNS) and
increased T-cell response against myelin. To understand whether the discrepant results obtained in KitW-sh/W-sh and in
KitW/W-v mice were because of the different immunization protocols, we induced EAE in these two strains with varying
doses of MOG35–55 and adjuvants. Although Kit
W-sh/W-sh mice exhibited exacerbated EAE under all immunization proto-
cols, KitW/W-v mice were protected from EAE only when immunized with high, but not low, doses of antigen and
adjuvants. KitW-sh/W-sh mice reconstituted systemically, but not in the CNS, with bone marrow-derived MCs still developed
exacerbated EAE, indicating that protection from disease could be exerted by MCs mainly in the CNS, and/or by other
cells possibly dysregulated in KitW-sh/W-sh mice. In summary, these data suggest to reconsider MC contribution to EAE,
taking into account the variables of using different experimental models and immunization protocols.
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MCs are key factors in IgE-associated immediate hypersensi-
tivity reactions, during which they release a wide spectrum of
inflammatory mediators in response to IgE and antigen (Ag)
stimulation.1 However, recent findings have pointed out that
MCs may exert also important effector and/or immuno-
modulatory functions in other physiopathological conditions
as venom detoxification, pathogen clearance, tumor growth,
contact hypersensitivity, allograft acceptance and auto-
immunity.2 Most of these studies have assessed the in vivo role
of MCs by the use of mouse models carrying spontaneous
mutations in c-Kit receptor (WBB6F1-Kit
W/W-v or C57BL/6-
KitW-sh/W-sh mice) or c-Kit ligand (WCB6F1-Kitl
Sl/KitlSl-d),
which show severe deficiency of MC populations.3,4
MCs may either enhance or suppress the inflammation asso-
ciated to different types of autoimmune diseases. MC-deficient
KitW/W-v and KitlSl/Sl-d mice are protected from autoantibody-
mediated models of rheumatoid arthritis and bullous pemphi-
goid, inflammatory disorders affecting, respectively, the joint and
the skin. Reconstitution of KitW/W-v mice with bone marrow
derived, in vitro cultured MCs (BMMCs) restores complete
disease susceptibility in both conditions, thus indicating a
proinflammatory role of these cells in such diseases.5,6 Con-
versely, MCs seem to exert a protective function in experimental
autoimmune glomerulonephritis, by limiting clinical and his-
tological glomerular pathology and mortality.7,8 However, recent
work has shown that, unlike KitW/W-v, KitW-sh/W-sh mice develop
a full clinical and histological autoimmune arthritis, thus ques-
tioning the actual involvement of MCs in this disorder.9
A complex and conflicting scenario emerges from studies
on the role of MCs in promoting central nervous system
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(CNS) autoimmune response occurring in multiple sclerosis
(MS) and its animal model, experimental autoimmune en-
cephalomyelitis (EAE).10 Several reports have documented
the presence of MCs within the plaques of MS patients, where
they are generally clustered around venules and capillaries,
in lower numbers in acute lesions than in chronic active
plaques.11,12 Gene microarray and quantitative RT-PCR
analyses have revealed that transcripts for MC-related genes
(ie, triptase and IgE Fce receptor I) are upregulated in MS
plaques13,14 and MC tryptase is also elevated in the spinal
fluid during MS relapses.15 In EAE, numerous studies have
reported a correlation between number, distribution and/or
activation state of brain MCs and the development and
severity of the disease.10 A significant support for a proin-
flammatory role of MCs in EAE derives from M Brown’s
group, showing that KitW/W-v mice develop EAE with delayed
onset and significantly milder severity as compared with
congenic Kitþ /þ mice.16 Reconstitution of these mice with
BMMCs derived from wild-type (WT) mice but not from
mice genetically lacking Fc receptors restores typical disease
susceptibility.17 Further studies have demonstrated that MCs
may exert their immune functions in this model by influ-
encing autoimmune T-cell responses in periphery, rather
than in the parenchyma of CNS, which is not repopulated in
KitW/W-v mice after BMMC transplantation.18 In line with
these findings, the analysis of draining lymph nodes during
acute EAE revealed activated MCs, regulatory T cells and
Th17 cells establishing tight spatial interactions, suggesting
the occurrence of a MC-mediated inhibition of regulatory
T-cell function in support of Th17 immune response.19
In KitW/W-v mice, MCs have also extra-lymphoid roles in
EAE, favoring the access of neutrophils to inflamed CNS by
secreting TNF in meninges.20
In contrast to these previous works, Bennett et al 21 have
recently shown that MCs are dispensable for EAE develop-
ment in both KitW/W-v and KitW-sh/W-sh models. Conversely,
Stelekati et al22 have recently published that EAE severity is
decreased in KitW-sh/W-sh mice but is restored following MC
knockin,22 thus confirming the data obtained by Brown and
colleagues in KitW/W-v model.
It is possible that discrepant results obtained on this topic
by different groups could in part be related to different
protocols of immunization used to elicit EAE, as well as to
different animal models of MC deficiency. Indeed, at least in
the KitW/W-v model, it has been shown that the doses of
adjuvant or peptide in immunization protocols can drasti-
cally affect MC involvement in the disease under investiga-
tion, as emerged in experimental models of asthma23 and
contact hypersensitivity.24
The aim of our study was to unravel the contribution of
MCs to EAE in both KitW-sh/W-sh and KitW/W-v strains by
using different protocols of immunization, in order to eval-
uate if disease outcome was affected by different experimental
settings. In this study, we report that, under three different
immunization conditions, KitW-sh/W-sh mice develop a more
severe EAE and an increased immune response against
myelin than Kitþ /þ animals. However, systemic reconstitu-
tion of KitW-sh/W-sh mice with BMMCs fails to restore WT
susceptibility, therefore suggesting that in this model per-
ipheral MCs may be redundant for EAE development. Sur-
prisingly, KitW/W-v mice are protected from EAE only when
immunized with a ‘strong’ protocol of immunization (ie,
with higher doses of Ag and adjuvants, similar to the one
used by Secor et al), but not when immunized with a milder
one. Thus, MC contribution to EAE pathogenesis needs to be
reconsidered, taking into account the variations because of
the different immunization conditions and genetic defects.
MATERIALS AND METHODS
Animals
c-Kit mutant C57BL/6-KitW-sh/W-sh mice and their WT con-
trols C57BL/6-Kitþ /þ , c-Kit mutant WBB6F1-Kit
W/W-v mice
and their congenic WT littermates WBB6F1-Kit
þ /þ , and
myelin oligodendrocyte glycoprotein (MOG)35–55-TCR
transgenic 2D2 mice were purchased from Jackson Labora-
tories. Age-matched female, 8- to 12-weeks-old mice, were
used in all EAE experiments. Mice were maintained under
pathogen-free conditions at the animal facility of Fondazione
IRCCS Istituto Neurologico ‘Carlo Besta’ Milano or of
Stanford University. All procedures involving animals were
approved by the Institute Ethical Committee and performed
in accordance to institutional guidelines and national law
(DL116/92) and the Division of Comparative Medicine at
Stanford University, and carried out according to the Prin-
ciples of Laboratory Animal Care (European Communities
Council Directive 86/609/EEC) and the National Institutes of
Health guidelines.
Peptide Synthesis, Protocols of Active and Passive EAE
and Granulocyte Depletion
MOG35–55 (MEVGWYRSPFSRVVHLYRNGK) and control
peptide (rat P0; DGDFAIVKFTKVLLDYTGHI) were syn-
thesized using a standard 9-fluorenylmethoxycarbonyl
chemistry on a 433A automated peptide synthesizer (Applied
Biosystems) and purified by HPLC. The purity of each
peptide was 495% as assessed by analytical reverse-phase
HPLC. EAE was induced with different protocols of immuni-
zation. For EAE induction in Figure 1a, MOG35–55 peptide
was dissolved in PBS to a concentration of 4 mg/ml and
emulsified with an equal volume of IFA supplemented with
8 mg/ml heat-killed Mycobacterium tuberculosis H37Ra (Dif-
co). Mice were injected s.c. in their flanks with 0.1 ml of the
peptide emulsion (for a total of 200 mg of MOG35–55/mouse
and 400 mg of M. tuberculosis) and, on the same day and at
48 h later, were injected i.v. with 0.2 ml containing 200 ng of
Bordetella pertussis Toxin (List Laboratories) dissolved in
PBS. Doses of MOG35–55 and adjuvants used in other pro-
tocols are specified in figure legends. Passive EAE was
induced as described in Yang et al.25 Briefly, splenocytes
from 2D2 mice were activated with MOG35–55 (20 mg/ml),
EAE in KitW-sh/W-sh mice
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Figure 1 MC-deficient KitW-sh/W-sh mice develop exacerbated EAE associated with increased CNS inflammation and autoimmune response. (a) EAE was
induced in Kitþ /þ (n¼ 10) and KitW-sh/W-sh (n¼ 17) mice with MOG35–55 peptide as detailed in Materials and Methods and mice were scored daily as
described.28 Data represent mean clinical score±s.e.m. (*Po0.05, ***Po0.005, ****Po0.001; Student’s t-test, two tailed). These data are from a single
experiment representative of three independent replicates, each including 9–17 mice per group. (b) Distribution and phenotype of the lesions in the CNS of
Kitþ /þ and KitW-sh/W-sh mice obtained at 7 weeks after EAE induction. The upper left images show representative brain sections from cerebellum (left panel)
and hippocampal/thalamic region (right panel) from KitW-sh/W-sh mice highlighting severe perivascular infiltrates (asterisk), as shown in detail in the
corresponding insets. Conversely, Kitþ /þ mice (upper right images) show no signs of active inflammation with few dilated vessels and rare inflammatory
cells (insets) both in the cerebellum (left panel) and in the hippocampal/thalamic region (right panel). Similar findings were observed in the spinal cords,
with the KitW-sh/W-sh mice showing severe perivascular inflammatory infiltrates (asterisk; left panels) and the Kitþ /þ mice being substantially free of
inflammatory cells with foci of residual myelin damage (asterisk) with microcystic appearance (inset). (c) Proliferation rate of LNCs (mean c.p.m.±s.e.m., from
triplicate wells) and (d) cytokine production of splenocytes (means±s.e.m., from duplicate wells) isolated from Kitþ /þ and KitW-sh/W-sh mice (n¼ 4 mice per
group) at 10 days after EAE induction and stimulated with MOG35–55, concanavalin A (conA) or medium alone. *Po0.05, **Po0.01, ***Po0.005 (Student’s
t-test, two tailed). (e) Representative graphs showing percentages of CD4þ IL-17þ and CD4þ IFN-gþ T cells in draining lymph node obtained from Kitþ /þ
and KitW-sh/W-sh mice at 10 days post-EAE induction. (f) Draining lymph node isolated from Kitþ /þ and KitW-sh/W-sh during acute (d10) and chronic (d48) EAE
display a different density of IL-10-expressing mononuclear cells (anti-IL-10, STREPT-ABC complex method; original magnification  200). (g) Anti-MOG35–55-
specific IgG antibodies and IgG antibody isotypes in sera from Kitþ /þ (n¼ 10) and KitW-sh/W-sh (n¼ 15) mice obtained at 7 weeks after the induction of EAE.
Each mouse was tested individually in duplicate. Bars represent mean titers±s.e.m.
EAE in KitW-sh/W-sh mice
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IL-2 (Proleukin) and IL-7 (Peprotech) for 2 days, expanded
with IL-2 and IL-7 for 5 days, restimulated overnight with
coated anti-CD3 (eBioscience), IL-12 (kindly provided by
Dr Maurice Gately, Hoffmann LaRoche, Nutley, NJ) and
IL-18 (R&D Systems) and i.p. injected (106/mouse). Mice
were assessed daily for neurological signs of EAE according to
the following five-point scale: (0) healthy; (1) tail weakness
or paralysis; (2) paraparesis (incomplete paralysis of one
or two hind limbs/plegia of one hind limb); (3) paraplegia
extending to the thoracic level; (4) forelimb weakness or
paralysis with hind limbs paraparesis or paraplegia; and (5)
moribund or dead animal. For granulocyte depletion, mice
were treated i.p. with 10 mg anti-Ly6G mAb (clone RB6-8C5)
dissolved in saline (200 ml) daily from d0 to d9.
Bone-Marrow-Derived MC Differentiation and Adoptive
Transfer into KitW-sh/W-sh Mice
BMMCs were obtained by in vitro differentiation of bone
marrow cells taken from mouse femurs as described.26 After 5
weeks, BMMCs were monitored for FceRI expression by flow
cytometry using FITC-conjugated anti-mouse FceRI-a (clone
MAR-1, eBioscience) and PE-Cy7-conjugated anti-mouse
c-Kit (clone 2B8, eBioscience). Purity was usually 490%.
BMMCs were obtained from pooled three to four mice
in each experiment. For MC-engraftment studies, BMMCs
derived from Kitþ /þ mice were injected i.v. into the tail vein
(107 cells in 400 ml PBS) into 4-weeks-old female KitW-sh/W-sh
mice. EAE experiments were initiated at 6–8 weeks after
adoptive transfer of BMMCs.
T-Cell Proliferation Assay and Cytokine Measurement
Draining lymph node cells (LNCs) were isolated from
KitW-sh/W-sh and Kitþ /þ mice at 10 days after the induction
of EAE, and they were cultured in vitro with MOG35–55, Con
A (1mg/ml; positive control), rat P0 (negative control) or
medium alone. Cells were cultured in 96-well microtiter
plates at a density of 4–5 105 cells/well in 200 ml of RPMI
1640 (EuroClone) supplemented with L-glutamine (2 mM),
sodium pyruvate (1 mM), nonessential amino acids
(0.1 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml),
2-ME (5 105 M), HEPES buffer (0.01 M) and 10% FCS
(enriched RPMI 1640). After 72 h of incubation at 371C with
5% CO2, cultures were pulsed for 18 h with 0.5 mCi of
[3H]thymidine per well and proliferation was measured from
triplicate cultures on a b-counter (PerkinElmer). Data are
expressed as mean c.p.m.±s.e.m. For cytokine analysis,
spleen cells were harvested from KitW-sh/W-sh and Kitþ /þ
mice at 10 days after the induction of EAE and cultured in
24-well plates (3.5 106 cells/well) with MOG35–55, Con A,
rat P0 or medium alone in the same conditions as described
above. Supernatants from in vitro-cultured spleen cells were
analyzed by ELISA for IFN-g, IL-6, IL-10 (anti-mouse Op-
tEIA ELISA Set; BD Pharmingen), and IL-17 (R&D Systems)
according to the manufacturer’s protocols. Supernatants were
collected from cultured cells at different time points: 24 h for
IL-6, 48 h for IFN-g and 96 h for IL-10 and IL-17. Results are
shown as mean of duplicates; s.e.m. were always within 10%
of the mean.
Flow Cytometry
PE-Cy7-conjugated anti-CD4 (clone L3T4), PE-conjugated
anti-CD11b (clone M1/70), FITC-conjugated anti-Gr1 (clone
RB6-8C5) were from eBioscience. FITC-conjugated anti-
Ly6G (clone 1A8) and APC-conjugated Ly6C (clone
1G7.G10) were from Miltenyi Biotec. Surface staining reac-
tions were performed in PBS supplemented with 2% FCS on
ice for 30 min. Intracellular staining with AlexaFluor647-
conjugated anti-IL17A (clone eBio17B7) and PE-conjugated
anti-IFN-g (clone XMG1.2) was carried out after 4 h stimu-
lation with Monensin solution (eBioscience), 50 ng/ml PMA
and 500 ng/ml ionomycin (Sigma-Aldrich). Staining with PE-
conjugated anti-Foxp3 mAb (clone FJK-16S) was performed
according to the manufacturer’s instructions (eBioscience).
Flow cytometry data were acquired on a FACSCalibur (Bec-
ton Dickinson) and analyzed with FlowJo software (version
8.8.6; Treestar).
Histopathology and Immunohistochemistry
For histological evaluation of EAE in KitW-sh/W-sh and Kitþ /þ
mice, five animals per group were killed at 7 weeks after the
induction of EAE, and the brain and spinal cord were re-
moved, fixed in 10% formalin and embedded in paraffin.
Sections (4 mm) were cut on a microtome and stained with
hematoxylin and eosin to study basic histopathological
changes. Sections were analyzed in a blinded manner (PLP).
The inflammatory changes were expressed as number of
perivascular inflammatory infiltrates per square millimeter in
the spinal cord27 or as number of inflammatory foci per
section, respectively, for the spinal cord and the brain.
Histopathological analysis of MC distribution in steady
state and inflamed tissues was carried out on toluidine blue-
stained sections from formalin-fixed, paraffin-embedded
samples. The number of MCs was estimated by counting
MCs out of five high-power microscopic fields ( 400)
showing the highest MC densities and then summing the
counts relative to each HPF. For immunohistochemical de-
tection of IL-10þ cells, sections from formalin-fixed, paraf-
fin-embedded lymph nodes underwent immunostaining with
the streptavidin biotin peroxidase complex method using a
specific primary anti-mouse IL-10 antibody (clone JES5-2A5,
eBioscience) and aminoethylcarbazole as chromogen. All the
immunostained sections were counterstained with hema-
toxylin. Slides were analyzed under a Leica DM2000 optical
microscope, and microphotographs were collected using a
Leica DFC320 digital camera.
Measurement of Serum Antibody Response
Blood was collected from the tail of KitW-sh/W-sh and Kitþ /þ
mice before and at 7 weeks after the induction of EAE.
MOG35–55-specific IgG, IgG1, IgG2a, IgG2b and IgG3 Abs
EAE in KitW-sh/W-sh mice
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were measured by ELISA as described elsewhere.28 Briefly, 96-
well microtiter plates (Immunol; Thermo Labsystems) were
coated overnight at 41C with 0.1 ml of MOG35–55 diluted in
0.1 M NaHCO3 buffer (pH 9.5) at a concentration of
0.010 mg/ml. The plates were blocked with PBS/10% FCS
(blocking buffer) for 2 h. Samples were diluted in blocking
buffer at 1/100, and Ab binding was tested by the addition of
peroxidase-conjugated monoclonal goat anti-mouse IgG,
IgG1, IgG2a, IgG2b and IgG3 (Southern Biotechnology
Associates), each at a 1/5000 dilution in blocking buffer.
Enzyme substrate was added and plates were read at 450 nm
on a microplate reader.
Statistical Analysis
Student’s t-test, two tailed, was used to compare the results
between the two groups. In all tests, Po0.05 was considered
statistically significant.
RESULTS
MC-Deficient KitW-sh/W-sh Mice Develop Exacerbated EAE
We first evaluated the involvement of MCs in EAE by using
the more recently characterized model of MC deficiency,
KitW-sh/W-sh mice, which seems to bear milder c-Kit-related
phenotypic abnormalities than KitW/W-v strain.29 Indeed,
KitW-sh/W-sh mice are not anemic, neutropenic or sterile as
KitW/W-v animals, although they are affected by some he-
matopoietic alterations such as splenomegaly with expanded
myeloid populations, and increased number of circulating
neutrophils and platelets.30 Chronic progressive EAE was
induced in MC-deficient KitW-sh/W-sh and Kitþ /þ mice by
immunization with MOG35–55. This protocol induces in this
strain a clinical course classically characterized by the acute
onset of neurological symptoms reaching a peak about
at 2 weeks after immunization, followed by a short and
generally incomplete recovery phase after which symptoms
of intermediate gravity are chronically maintained.28,31
Surprisingly, KitW-sh/W-sh mice developed exacerbated
EAE compared with Kitþ /þ mice (Figure 1a, Table 1),
characterized by an anticipated onset and a more severe
progression. The clinical severity of EAE was significantly
worsened in KitW-sh/W-sh mice during both recovery and
chronic phases of disease (mean disease score was 1.8±0.2
in Kitþ /þ vs 2.8±0.3 in KitW-sh/W-sh mice (Po0.05) at day
20 (recovery phase), and 1.8±0.2 in Kitþ /þ vs 2.6±0.3 in
KitW-sh/W-sh mice (po0.05) at day 43 (chronic phase)). The
clinical data were corroborated by a histopathological ana-
lysis of CNS inflammation in the chronic phase that revealed
more inflammatory foci in the CNS of KitW-sh/W-sh compared
with Kitþ /þ mice (2.17±1.15 vs 0.75±0.79/mm2, respec-
tively, Po0.05, in the spinal cord; 2.08±1.49 vs 0.83±0.76/
section, respectively, P40.05, in the brain; Figure 1b).
MCs can limit the magnitude of some adaptive immune
responses by establishing functional interactions with reg-
ulatory T cells32 or by secreting IL-10.33 Given the increased
EAE severity shown by KitW-sh/W-sh mice, we investigated
whether the peripheral immune response against myelin was
affected by MC deficiency. For this purpose, we isolated
draining lymph nodes and spleens from mice with EAE at 10
days after immunization. LNCs from KitW-sh/W-sh mice
showed a significantly increased proliferation in response to
MOG35–55 (Figure 1c) and Ag-stimulated splenocytes from
these mice produced significantly more IL-17 and IL-6, but
less IL-10, than Kitþ /þ animals (Figure 1d). There were no
significant differences in the production of IFN-g (Figure
1d). Percentages of IL-17þ CD4 T cells (0.9±0.4 in Kitþ /þ
vs 2.2±0.2 in KitW-sh/W-sh mice, Po0.05) and IFN-gþ CD4
T cells (1.2±0.2 in Kitþ /þ vs 2.5±0.6 in KitW-sh/W-sh
mice, P40.05) were also increased in lymph nodes
from KitW-sh/W-sh mice compared with Kitþ /þ animals
(Figure 1e). Immunohistochemical analysis of lymph node
sections revealed few scattered IL-10þ cells in KitW-sh/W-sh
and control Kitþ /þ samples from the acute phase. In these
samples, a slight difference was observed in the amount
of IL-10þ mononucleated cells between KitW-sh/W-sh and
Kitþ /þ mice. Such a difference was more evident in samples
from the chronic phase, in which the overall amount of
IL-10þ cells was higher (Figure 1f). In line with these results,
intracellular staining of IL-10 showed a slightly decreased
IL-10 content in CD4 T cells in KitW-sh/W-sh mice in both the
acute and chronic phases (Supplementary Figure S1).
MCs have been described to enhance IgE and IgG1 pro-
duction by B cells34,35 and to secrete cytokines affecting B-cell
responses such as IL-4, IL-5 and IL-13.1 Analysis of Ab re-
sponses in sera from immunized KitW-sh/W-sh and Kitþ /þ
mice (Figure 1g) revealed a slight but not significant decrease
in titers of IgG antibodies specific for MOG35–55 in MC-
deficient mice (mean OD, 0.190±0.074 in Kitþ /þ vs
0.079±0.047 in KitW-sh/W-sh mice; P¼ 0.194). Analysis of the
IgG isotypes showed decreased titers of Ag-specific IgG2b
Abs in KitW-sh/W-sh compared with Kitþ /þ mice (mean OD,
0.890±0.477 in Kitþ /þ vs 0.177±0.124 in KitW-sh/W-sh mice,
P¼ 0.178) but not of the other IgG isotypes.
We19,26 and others32,36,37 have reported that MCs can ar-
range several kinds of interaction with Treg. We tested
whether KitW-sh/W-sh mice harbored some alteration in the
Treg compartment. We found a significantly lower Treg
frequency in spleens, but not in draining lymph nodes, of
Table 1 EAE in KitWsh/Wsh and Kit+/+ wild-type mice
Strain Incidence
(%)a
EAE onset,
daya
Peak disease
severitya
Cumulative
disease scorea
KitWsh/Wsh 100 (17/17) 7.0±0.5z 3.8±0.2 109.9±9.5w
Kit+/+ 90 (9/10) 9.8±0.8 3.3±0.4 78.9±9.5
Abbreviation: EAE, autoimmune encephalomyelitis.
a
Data are shown as mean±s.e.m.
w
Po0.05.
z
Po0.01 (all P-values are in comparison with Kit+/+ wild-type mice by Student’s
t-test, two tailed).
EAE in KitW-sh/W-sh mice
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KitW-sh/W-sh compared with Kitþ /þ mice, at both d10 and
d42 after immunization (Supplementary Figure S2). How-
ever, the fraction of Treg among CNS-infiltrating CD4 T cells
at d10 post immunization did not differ between KitW-sh/W-sh
and controls (Supplementary Figure S2C). A decrease in Treg
frequency was also observed in lymph nodes of naive
KitW-sh/W-sh compared with Kitþ /þ mice (Supplementary
Figure S3).
We evaluated the amount and distribution of MCs by
histopathological evaluation of toluidine-blue-stained sec-
tions. In both naive and immunized Kitþ /þ mice only few
MCs were detected in the CNS, mostly associated with the
meninges. MCs infiltrating the brain or spinal cord par-
enchyma were only exceptionally observed in immunized
Kitþ /þ mice. The amount and distribution of MCs in
draining lymph nodes were affected by immunization, as
lymph nodes from naive mice showed few MCs mainly
lodged inside the sinuses or within the medullary area (not
shown), whereas those from immunized mice showed higher
numbers of MCs either scattered or clustered within the
T-cell-rich perifollicular areas (Figure 2). In naı¨ve and im-
munized KitW-sh/W-sh mice, no MCs were detected in the CNS
parenchyma. Draining lymph nodes from the same mice were
characterized by a hypertrophic medulla with dilated sinuses
and by the absence of MCs (Figure 2).
KitW-sh/W-sh Mice Develop Severe EAE Regardless the
Immunization Protocol
Clinical and immunological findings obtained by us in the
KitW-sh/W-sh model were in contrast with the work by Secor
et al16 showing that MC-deficient KitW/W-v mice develop
a milder EAE associated with a reduced proinflammatory
autoimmune response.38 However, in these studies, a ‘strong’
protocol of immunization (ie, high doses of MOG35–55, heat-
killed Mycobacterium tuberculosis in CFA and Bordetella
pertussis toxin (PTX)) was used to induce EAE. To evaluate
whether the discrepant outcome obtained by us in the
KitW-sh/W-sh strain could depend on the specific conditions of
immunization, we induced EAE in KitW-sh/W-sh and Kitþ /þ
mice by two additional protocols of immunization stronger
than the one used in Figure 1, containing increased doses of
PTX or, similarly to Secor et al, higher doses of MOG35–55,
M. tuberculosis and PTX. We observed that KitW-sh/W-sh mice
developed a more severe EAE than controls (Figure 3a and b)
also under these conditions of immunization. Interestingly,
immunization with the strongest protocol (Figure 3b)
resulted in a more significant clinical difference between
KitW-sh/W-sh and Kitþ /þ mice. Analysis of the peripheral
immune response against MOG35–55 during the acute phase
of disease induced with both protocols of immunization
confirmed an increased proinflammatory profile of immune
cells from KitW-sh/W-sh compared with those from Kitþ /þ
mice (data not shown).
MCs Promote or Inhibit EAE in KitW/W-v Mice Depending
on the Conditions of Immunization
Given the surprising observation of exacerbated EAE in ab-
sence of MCs in the KitW-sh/W-sh mouse model, we decided to
go back to the KitW/W-v mouse model and to study the
disease in these mice by using different protocols of im-
munization as we did in the KitW-sh/W-sh mice. We induced
EAE with our standard protocol of immunization or with a
‘stronger’ one similar to that used by Secor et al.16 Surpris-
ingly, with lower doses of Ag and adjuvants, KitW/W-v mice
Figure 2 Mast cell distribution in brain, spinal cord and draining lymph node (DLN) of Kitþ /þ and KitW-sh/W-sh EAE mice. In immunized Kitþ /þ mice few MCs
populate the CNS, mostly localized within the meninges. In DLNs from the same mice, small clusters of MCs can be observed in the perifollicular areas of the
cortex. In KitW-sh/W-sh mice, no MCs can be detected in either the CNS or DLNs. (Toluidine blue; original magnification  100, inset  400.)
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exhibited a more severe disease course than controls,
resembling the phenotype observed in the KitW-sh/W-sh strain
(Figure 4a). Conversely, when we applied a ‘stronger’ pro-
tocol of immunization, KitW/W-v mice developed a sig-
nificantly milder EAE compared with Kitþ /þ mice,
confirming a detrimental role for MCs in EAE under these
specific experimental conditions (Figure 4b).
Systemic Reconstitution of KitW-sh/W-sh Mice with BMMCs
Fails to Revert EAE Phenotype
To test whether the different EAE severity of Kitþ /þ and
KitW-sh/W-sh mice was truly due to the absence of MCs, rather
than to other c-Kit-related alterations,30 KitW-sh/W-sh mice
were engrafted with BMMCs differentiated from Kitþ /þ
donors. Intravenous route of transplantation allowed
repopulation of peripheral lymphoid organs, although, as
previously observed,29,39 MC reconstitution did not restore
the physiological MC distribution observed in WT mice
(Figure 5a). Also, BMMC i.v. transplantation failed to
repopulate the CNS (Figure 5a), as already reported in
BMMCs-reconstituted KitW/W-v mice.18 Of note, we observed
that Treg deficiency was corrected in lymph nodes of
BMMCs-reconstituted naive KitW-sh/W-sh mice (Supplemen-
tary Figure S3). As shown in Figure 5c, BMMCs-transplanted
KitW-sh/W-sh mice developed EAE similarly to MC-deficient
KitW-sh/W-sh mice. These data suggest that in this model the
restoration of a peripheral pool of MCs is not sufficient to
recapitulate WT disease course, at least during the priming
phase.
Passive EAE is Exacerbated in KitW-sh/W-sh Mice
The above data indicated that c-Kit mutation affects the
development of autoimmune manifestations mainly outside
Figure 3 KitW-sh/W-sh mice develop exacerbated EAE under different
conditions of immunization. EAE was induced by two additional protocols
of immunization bearing increased doses of sole PTX or of both adjuvants
and myelin peptide. (a) Kitþ /þ (n¼ 10) and KitW-sh/W-sh (n¼ 9) were
immunized by s.c. injection of 200 mg of MOG35–55 emulsified in complete
Freund’s adjuvant containing 400 mg of M. tuberculosis (on day 0) and i.v.
injection of 400 ng of PTX (on days 0 and þ 2). (b) Kitþ /þ (n¼ 9) and
KitW-sh/W-sh (n¼ 10) were s.c. injected with 300 mg of MOG35–55 emulsified
in complete Freund’s adjuvant containing 500 mg of M. tuberculosis (on days
0 and þ 7) and i.v. injected with 400 ng of PTX (on days 0 and þ 2).
Mice were scored daily. Data represent mean clinical score±s.e.m. from
a representative experiment out of two independent replicates, each
including 4–10 mice per group, carried out for each protocol of
immunization (*Po0.05, **Po0.01, ***Po0.005, ****Po0.001; Student’s
t-test, two tailed).
Figure 4 KitW/W-v susceptibility to EAE depends on the protocols of
immunization. (a) Kitþ /þ (n¼ 15) and KitW/W-v (n¼ 15) were immunized
with 100 mg of MOG35–55 emulsified in complete Freund’s adjuvant
containing 200 mg of M. tuberculosis (s.c. on day 0) and 200 ng of PTX (i.v. on
days 0 and þ 2). (b) Kitþ /þ (n¼ 10) and KitW/W-v (n¼ 10) were immunized
as described in Figure 3b. Mice were scored daily. Data represent mean
clinical score±s.e.m. from a single experiment performed for each protocol
of immunization (*Po0.05, **Po0.01; Student’s t-test, two tailed).
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the peripheral lymphoid organs, suggesting that an altered
encephalitogenic T-cell priming was unlikely responsible for
the exacerbated disease course observed in KitW-sh/W-sh mice.
To confirm this hypothesis, passive EAE was induced in
KitW-sh/W-sh and Kitþ /þ mice by transferring in vitro primed
MOG35–55-specific TCR-transgenic 2D2 T cells.
25 This ap-
proach allowed uncoupling priming and effector phase of the
disease and isolating the role played by c-Kit mutation in
inflammation in the CNS. We found that, also in this setting,
KitW-sh/W-sh mice developed clinical signs of disease with
anticipated onset and exacerbated severity compared with
Kitþ /þ mice (Figure 5d). This result suggested that the
major contribution of the KitW-sh/W-sh mutation to EAE pa-
thology occurred downstream T-cell priming and concerned
probably the effector phase of the disease mounting in
the CNS.
Alterations in the Granulocyte Compartment do not
Influence EAE in KitW-sh/W-sh Mice
KitW-sh/W-sh mutation may affect the homeostasis of granu-
locyte populations expressing c-Kit.29,30 As granulocytes
participate as effector cells in autoimmune inflammation in
the CNS during EAE,40,41 we speculated that enhanced
granulocytosis might contribute to disease exacerbation in
KitW-sh/W-sh mice. We first characterized the percentage of
Gr1hi CD11bhi and Gr1int CD11bint myeloid populations in
the lymphoid organs of naive Kitþ /þ and in KitW-sh/W-sh
animals. We observed a higher percentage of both subsets in
Figure 5 Mast cell reconstitution fails to attenuate EAE clinical severity in KitW-sh/W-sh mice. (a, b) BMMCs were engrafted i.v. (107 cells/mouse) in KitW-sh/W-sh
mice, and MC distribution in multiple organs was analyzed at 6–8 weeks later by toluidine blue staining. (a) Intravenously-injected MCs repopulated tissues
of KitW-sh/W-sh mice and preferentially accumulated in the spleen, liver and lung. The number of MCs was estimated by counting MCs in five high-power
microscopic fields ( 400) showing the highest MC densities and then summing the counts relative to each high-power field. Data represent mean cell
counts in each organ±s.e.m. (*Po0.05, ***Po0.005; Student’s t-test, two tailed, calculated between Kitþ /þ and BMMCs-engrafted KitW-sh/W-sh mice).
(b) Inguinal LN (IngLN) from reconstituted KitW-sh/W-sh mice showed a comparable amount of MCs with LN from WT mice, though the distribution of MCs in
repopulated LNs was mainly intrasinusoidal (toluidine blue; original magnification  100, inset  400). (c) EAE was induced in Kitþ /þ , KitW-sh/W-sh and
BMMCs-transplanted KitW-sh/W-sh mice with MOG35–55 peptide as described in Materials and Methods. BMMCs were injected i.v. at 6–8 weeks before
immunization. These data are from a single experiment representative of two independent replicates, each including 4–10 mice per group. (d) Passive EAE
was induced in Kitþ /þ (n¼ 7) and KitW-sh/W-sh (n¼ 10) mice by i.p. injection of in vitro primed MOG35–55-specific TCR-transgenic 2D2 T cells. Mice were
scored daily. Data represent mean clinical score±s.e.m. from a representative experiment out of two independent replicates, each including 7–10 mice per
group (*Po0.05, **Po0.01, ***Po0.005; Student’s t-test, two tailed).
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the spleens of KitW-sh/W-sh mice compared with controls,
according to previous findings,30 whereas only the Gr1hi
CD11bhi population was expanded in their lymph nodes
(Supplementary Figure S4A). The anti-Gr1 mAb used for
staining (RB6-8C5 clone) recognized both Ly6Gþ and
Ly6Cþ subsets,42 representing granulocytic and monocytic
cells, respectively. The analysis of these two populations
showed that both Ly6Gþ and Ly6Cþ cells were expanded in
the spleens of KitW-sh/W-sh mice, but only the Ly6Gþ
CD11bþ subset was amplified in lymph nodes (Supple-
mentary Figure S4B). The Gr1hi CD11bhi population ex-
pressed c-Kit at higher level than the Gr1int CD11bint
counterpart in Kitþ /þ mice; moreover, c-Kit expression in
the Gr1hi CD11bhi compartment was significantly decreased
in KitW-sh/W-sh mice, whereas remaining unaltered within the
Gr1int CD11bint counterpart (Supplementary Figure S4C).
These pieces of evidence suggested that Gr1hi CD11bhi cells
(likely encompassing the Ly6Gþ granulocytes) were more
strictly dependent on c-Kit signal for their homeostasis than
the Gr1int CD11bint cells (including the Ly6Cþ monocytes).
To explore the effects of KitW-sh/W-sh mutation in the ex-
pansion of myeloid cells upon EAE induction, we looked at
the frequency of CD11bþ , Ly6Gþ and Ly6Cþ cells in lym-
phoid organs and CNS on immunization. The percentage of
total CD11bþ cells was higher in draining lymph nodes of
KitW-sh/W-sh mice compared with controls at d10 after
immunization. A faster accumulation of the Ly6Gþ , rather
than the Ly6Cþ , fraction mainly accounted for this differ-
ence between the two strains (Figure 6a and b). At d10, the
leukocytes infiltrating the CNS of KitW-sh/W-sh mice contained
a higher fraction of Ly6Gþ CD11bþ cells, suggesting that an
enhanced granulocyte-mediated inflammation might corre-
spond to a peripheral granulocyte expansion (Figure 6c and d).
To identify the contribution of granulocyte expansion to the
increased disease severity expressed by KitW-sh/W-sh mice,
active EAE was induced in MC-deficient and WT mice under
a granulocyte-depleting regimen. To this aim, mice were
treated i.p., daily from d0 to d9, with the anti-Gr1 RB6-8C5
clone, which specifically depleted Ly6Gþ while sparing
Ly6Cþ cells (Figure 6f), according to published results.43
In line with previous findings,41 granulocyte elimination
importantly delayed the onset and attenuated the severity
of EAE symptoms in Kitþ /þ mice (Figure 6e). However,
although Ly6Gþ -depleted KitW-sh/W-sh mice developed
a milder disease than Kitþ /þ untreated controls, these mice
still developed a more severe disease than Ly6Gþ -depleted
Kitþ /þ controls, suggesting a granulocyte-independent me-
chanism behind enhanced autoimmune inflammation in
c-Kit mutated mice (Figure 6e). In support of this conclusion,
we observed that in BMMC-i.v. reconstituted KitW-sh/W-sh
mice, in which the normal disease course was not rescued
(Figure 5c), alterations of granulocyte homeostasis were
completely recovered in both the Gr1hi and Gr1int compart-
ments (Supplementary Figure S5). We noticed decreased
T-cell proliferation and inflammatory cytokine production in
both Ly6Gþ -depleted KitW-sh/W-sh and Kitþ /þ compared
with untreated Kitþ /þ mice. This suggests that the increased
disease severity observed in granulocyte-depleted KitW-sh/W-sh
compared with granulocyte-depleted Kitþ /þ mice was not
due to differences in T-cell peripheral activation (Figure 6g).
Taken together, these data suggest that KitW-sh/W-sh mice
developed exacerbated EAE independently from T-cell
priming, peripheral MC presence or granulocytic effector cell
alterations.
Beside MCs, other cells of the immune system may express
c-Kit at variable levels and under different circumstances,44
such as dendritic cells (DCs).45 C-Kit pharmacological
inhibition fosters a productive cross-talk between DCs and
natural killer (NK) cells 46 and promotes the differentiation
of a DC subset endowed with cytotoxic ability and IFN-g
competence.47 However, as previously reported,29 we did not
observe any difference between naive KitW-sh/W-sh and Kitþ /þ
mice in NK or DC frequency in the spleen (Supplementary
Figure S6).
DISCUSSION
Broad evidence suggests that MCs may have multiple and
even divergent roles in autoimmune and inflammatory dis-
eases. The vast majority of these observations come from
rodent MC-deficient models harboring different mutations
in the c-Kit gene. In this study, we showed that the KitW/W-v
animals were differentially susceptible to EAE induction
depending on the strength of the immunization protocol.
Conversely, KitW-sh/W-sh mice developed anticipated and ex-
acerbated EAE, either passively or actively induced, under all
the tested conditions of immunization. Such behavior could
not be attributed to an immunoregulatory role of MCs in
T-cell priming occurring in lymphoid organs, as indicated by
the failure of recovering the normal disease course by re-
constituting the peripheral MC pool or by passively inducing
EAE bypassing T-cell priming. We confirmed some defects in
the granulocyte compartment in KitW-sh/W-sh mice that might
participate to inflammation in the CNS, although granulo-
cyte elimination could not abrogate the difference in disease
outcome between c-Kit mutant and WT mice.
Most of the information about the role of MCs in EAE
came from the Brown’s group that showed decreased EAE
onset and severity in KitW/W-v mutant mice.16,38 In their
system, MC systemic reconstitution restored disease severity
by recovering an efficient encephalitogenic T-cell response in
peripheral lymphoid organs18 and by restoring neutrophil
penetration at the blood–brain barrier.20 Our results
reconciled, in part, the apparently contrasting findings in the
two MC-deficient strains. Indeed, we could reproduce
Brown’s data in the KitW/W-v model when a strong im-
munization protocol was applied, but under milder condi-
tions, which are our standard procedure to induce active
EAE,48 KitW/W-v mice developed an exacerbated rather than
an attenuated disease, replicating our results in the
KitW-sh/W-sh model. However, our results are in contrast with
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a recent report from the same group, showing decreased EAE
symptoms in KitW/W-v mice compared with Kitþ /þ mice also
on the application of a relatively milder immunization pro-
tocol (100 mg of MOG35–55 and 250 ng of PTX).
20 Thus, the
discrepancies between our results and those reported by the
Brown’s group remain to be fully understood. However, it is
possible that the opposite results observed in KitW/W-v under
different immunization protocols are related to a differential
impact of the same mutation on distinct pathological
mechanisms depending on the quality/quantity of the
immune stimulation and on experimental conditions.
Furthermore, different mutations in the same gene/locus can
lead to contrasting outcomes under the same conditions of
stimulation. Indeed, high doses of MOG35–55, CFA and PTX
produced a milder outcome in KitW/W-v mice, but a more
severe disease in KitW-sh/W-sh mice than in Kitþ /þ controls.
The reasons for this discrepancy may rely on differences
between strains regarding non-MC-related abnormalities.
For instance, it has been shown that KitW/W-v, but not
KitW-sh/W-sh, mice are resistant to antibody-induced arthritis
because the former is neutropenic, whereas the latter shows
splenic myeloid hyperplasia, both at basal level and on
Figure 6 The severe abnormalities in granulocyte compartment of KitW-sh/W-sh mice are not responsible for increased EAE severity. (a–d) The percentage of
total CD11bþ and the fraction of Ly6Gþ /Ly6Cþ cells among the CD11bþ compartment was evaluated by flow cytometry in inguinal lymph nodes (a, b) or
CNS (c, d) from Kitþ /þ and KitW-sh/W-sh mice at days 0, 4 or 10 after immunization. Data in a and c represent mean percentage±s.e.m. (*Po0.05, **Po0.01,
***Po0.005; Student’s t-test, two tailed). Representative contour plots of Ly6C vs Ly6G in gated CD11bþ cells are depicted in b and d. (e) Kitþ /þ (n¼ 14)
and KitW-sh/W-sh (n¼ 6) mice were immunized with MOG35–55 peptide. Kitþ /þ (n¼ 7) and KitW-sh/W-sh (n¼ 6) were treated with anti-Ly6G mAb as described in
Materials and Methods. The second cohort of Kitþ /þ mice (n¼ 7) was not treated and served as an internal control of EAE. Mice were scored daily. Data are
from a single experiment representative of two independent replicates, each including six to seven mice per group. Data represent mean clinical
score±s.e.m. (*Po0.05, **Po0.01, ***Po0.005; Student’s t-test, two tailed, calculated between a-Ly6G-treated Kitþ /þ and a-Ly6G-treated KitW-sh/W-sh mice).
(f) Representative contour plots showing depletion of Ly6Gþ but not Ly6Cþ cells in peripheral blood at 8 days after a-Ly6G treatment. (g) Proliferation rate
of LNCs (mean c.p.m.±s.e.m., from triplicate wells) and cytokine production of splenocytes (means±s.e.m., from duplicate wells) isolated from untreated
Kitþ /þ mice and from anti-Gr1-treated Kitþ /þ and KitW-sh/W-sh mice (n¼ 3–7 mice per group) at 10 days after EAE induction and stimulated with MOG35–55
10 mg/ml or medium alone. **Po0.01, ***Po0.005 (Student’s t-test, two tailed, calculated in comparison with untreated Kitþ /þ mice).
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immunization.9,30 Depletion of Gr1þ cells showed a
prominence of granulocytes, rather than MCs, in the pa-
thogenetic mechanisms driving arthritis in this model.9
The divergent susceptibility of the two strains to EAE
development may even reside in non-immune-related
processes. The observation that the KitW-sh/W-sh mutation
determines the disruption of the Corin gene30 suggests that
the KitW-sh/W-sh model may recapitulate the defects observed
in Corin/ mice. Indeed, KitW-sh/W-sh mice show cardio-
megaly30 and may also display spontaneous hypertension, a
condition associated to Corin ablation49 that may favor EAE
development, as indicated by the recent observation that
anti-hypertensive drugs suppress autoimmune response in
EAE.50 The KitW-sh/W-sh mutation may also produce dysre-
gulations in a series of genes included in the inverted region,
whose effects in immunity are largely unknown.30 Finally, the
two c-Kit-mutated strains differ in their genetic background,
and the WBB6F1-Kit
þ /þ is characterized by higher number of
peritoneal MCs and neutrophils than the C57BL/6-Kitþ /þ .51
In summary, our findings underscore the need for clear and
doubtless identification of the role of MCs in a certain process
by taking advantage of different c-Kit mutants. These variables
(the strain of MC-deficient mice, the kind of mutation in c-Kit
gene and the experimental model) are well exemplified by the
work of Piliponsky et al 52 in mouse models of sepsis. This
study demonstrates that MCs can promote survival in cecal
ligation and puncture (CLP) of moderate severity in WBB6F1-
KitW/W-v, C57BL/6-KitW-sh/W-sh and WBB6F1-KitW-sh/W-sh
strains, but they exert no effect in WBB6F1-KitW/W-v and
WBB6F1-KitW-sh/W-sh affected by severe CLP and increase
mortality in C57BL/6-KitW-sh/W-sh with severe CLP or infected
with Salmonella typhimurium.52
Also, indirect support to our results may come from
other mutant mice carrying quantitative or qualitative
defects in the MC population. Some of us have recently
reported a more severe EAE in histidine decarboxylase
(HDC)-deficient mice,28 which are not only genetically un-
able to produce histamine, but also show paucity in MC
number and abnormalities in MC cytoplasmic granules.53
Therefore, it is possible that these mice share with
c-Kit mutants the phenotypical defects that depend on MC
ablation. It must be noted that some of the results here re-
ported may be associated also to an alteration of histamine
signalling in these MC-deficient mice, as histamine has been
lately reported to reduce T cell proliferation and IFN-g
production in autoreactive T cells.54
Our data also show some discrepancy with the results
obtained by other groups in the KitW-sh/W-sh strain, showing
unchanged21 or reduced22 EAE clinical course in these mice
in comparison with WT counterpart. The former study
highlights that MCs accumulate in the CNS trafficking from
the bone marrow during EAE but are dispensable for the
development of the disease.21 Interestingly, although in this
study no difference in EAE expression between KitW-sh/W-sh
and Kitþ /þ mice was observed, an increased Ag-specific
T-cell proliferation in immunized KitW-sh/W-sh mice was
reported, in line with our findings. The latter study shows
that milder clinical signs of EAE in KitW-sh/W-sh mice correlate
with decreased CD8þ T-cell activation.22 Although the rea-
sons for these discrepancies still need to be determined, we
cannot exclude that different mouse housing conditions may
affect the outcome of the KitW-sh/W-sh mutation in EAE de-
velopment, a process dependent on the composition of the
gut microflora,55 which in turn may be modulated in a
context of MC deficiency.56 Moreover, environmental stress
may modulate autoimmunity development in experimental
models57 and MCs possess well-known abilities to translate
neurological into immunological signals.58
MC-knockin mouse models are useful tools to attribute a
specific role to MCs or to a MC-expressed molecule in a
particular biological process or pathological condition.29
Indeed, reconstitution of c-Kit mutant mice with in vitro
differentiated MCs should recover only MC-dependent
defects independently from the kind of c-Kit mutation.
Different routes can be used to transfer BMMCs attaining
different outcomes. Systemic intravenous injection produced
MC accumulation but altered distribution in blood-draining
organs with only a modest repopulation at priming sites, ie,
the inguinal and axillary lymph node, and in the neighboring
skin, according to previous data.29,39 In particular, the spleen
has been recognized to trap most of i.v.-injected MCs,
thus inhibiting their spreading to other tissues.39 Thus,
intravenous injection of BMMCs may inefficiently reproduce
the topography and the quantity of MCs observed in lym-
phoid organs of Kitþ /þ mice in physiological conditions.
However, we could detect the rescue of some MC-related
biological functions, such as the recovery of normal Treg and
granulocyte frequency, in lymph nodes and spleens, respec-
tively, of reconstituted mice. In these conditions, MC transfer
failed to recover the normal disease course. Although we
cannot exclude that the altered MC distribution at priming
sites, especially at draining lymph nodes, might have influ-
enced the clinical outcome of EAE in these reconstituted
mice, this result suggests that an immunoregulatory role of
MCs in the priming phase of EAE is unlikely. According to
previous results in the KitW/W-v strain,18 injected BMMCs
failed to repopulate the CNS parenchyma, therefore this ex-
perimental setting was not suitable to ascertain whether MCs
exerted a regulatory role directly in the inflamed milieu of the
CNS. Therefore, tissue-specific MC knockin should be ob-
tained, when possible, by localized MCs injections in order to
allow optimal and physiological repopulation. Intravenous or
intracranial injection of BMMCs has been recently found to
restore the pool of meningeal MCs in KitW/W-v mice, leading
to the recovery of a WT-like disease course and to the rescue
of neutrophil infiltration in the CNS.20 In our system,
although detecting scattered MCs in Kitþ /þ mice in the
context of the reticulum formed by the arachnoid, the sub-
dural neurothelium, and the dura mater, in line with pre-
vious observations,29 we could not find MCs populating the
EAE in KitW-sh/W-sh mice
S Piconese et al
www.laboratoryinvestigation.org | Laboratory Investigation | Volume 91 April 2011 637
meninges in BMMC-reconstituted KitW-sh/W-sh mice (not
shown).
To explore the contribution of immune cells other than
MCs in the observed phenotype, we checked the defective
frequency of other c-Kit-related cells, such as NK and
DCs,45–47 in KitW-sh/W-sh mice, without finding any differ-
ence, according to previous data.29 However, we cannot
exclude that DC-expressed c-Kit has some role on
immunization, as demonstrated in a model of allergic asth-
ma, in which Ag/adjuvant exposure induced on DCs the
expression of both c-Kit and its ligand, promoting Th2 and
Th17 responses.45 We then focused our attention on granu-
locytes because of their reported altered homeostasis in
KitW-sh/W-sh mice30 and their involvement in EAE patho-
genesis.41 Confirming previous results,30 we found an ex-
panded myeloid compartment in the spleens of KitW-sh/W-sh
mice, involving both the Gr1hiCD11bhi and the Gr1int
CD11bint subsets. We further characterized these myeloid
cells for the Ly6G and Ly6C markers, and found that both
subpopulations were expanded in the spleens of KitW-sh/W-sh
animals. We looked at the frequency of these cells also in
lymph nodes hosting encephalitogenic T-cell priming and
found Gr1hiCD11bhi and Ly6GþCD11bþ cells, but not
Gr1int CD11bint or Ly6CþCD11bþ cells, selectively ex-
panded by the c-Kit mutation. As the anti-Gr1 mAb used to
stain granulocytes reacts with both Ly6G and Ly6C mole-
cules,42 it was not possible to ascertain whether the Ly6Cþ
entirely corresponded to the Gr1int and the Ly6Gþ to the
Gr1hi subset. We found that the whole CD11bþ compart-
ment expressed c-Kit, although at a lower level than MCs
(not shown), but the c-Kit expression level varied between
different subsets and different genotypes, being higher in WT
Gr1hiCD11bhi cells compared with mutated Gr1hiCD11bhi,
WT Gr1intCD11bint and mutated Gr1intCD11bint cells. These
data confirm that, contrary to the KitW/W-v, the KitW-sh/W-sh
mutation does not produce an indiscriminate functional
knockdown of the c-Kit receptor. Rather, the inversion in a
regulatory element upstream the c-Kit gene may finely reg-
ulate the effects of c-Kit expression not only in MCs, but also
in other cells expressing c-Kit under different transcriptional
stimuli. In line with this hypothesis, we found that the
Gr1hiCD11bhi compartment seemed more strictly related to
the KitW-sh/W-sh mutation than the Gr1intCD11bint counter-
part, in terms of peripheral lymphoid accumulation/homing
and c-Kit expression level. However, our data also suggest
that granulocyte abnormalities detected in KitW-sh/W-sh mice
may be ascribed to granulocyte-extrinsic defects, as we could
rescue a normal myeloid compartment in the spleens fol-
lowing systemic MC reconstitution. On the contrary, in the
KitW/W-v model, the failure to correct peripheral neutropenia
with BMMC reconstitution suggests a neutrophil-intrinsic
role of the KitW/W-v mutation in shaping the granulocyte
compartment.20 It could be proposed that, in KitW-sh/W-sh
mice, MCs may actively inhibit granulopoiesis by unknown
mechanisms, or passively limit excessive myeloid expansion
simply by sequestering the majority of locally available,
paracrine or juxtacrine, SCF through the highly expressed
c-Kit receptor. This observation suggests to carefully interpret
the data obtained in MC-knockin experimental systems, as
also non-MC-related defects may be corrected by MC
transfer.
We confirmed myeloid cell expansion in the spleen (not
shown) and in draining lymph nodes of MOG35–55-im-
munized mice, involving both Ly6Gþ and Ly6Cþ com-
partments. The latter has been recently identified as a
monocytic immunosuppressive subset that expanded at EAE
onset and inhibited ex vivo T-cell proliferation, thus being
attributed to the family of myeloid-derived suppressor cells.59
However, the in vivo suppressive function of Ly6Cþ cells in
EAE has been questioned by the observation of an attenuated
disease development upon Ly6Cþ cell pharmacological
elimination.60 Conversely, the Ly6Gþ fraction was not sup-
pressive ex vivo59 and accordingly Ly6G elimination strongly
inhibited the development of both active and passive EAE,
suggesting an involvement of granulocytes in the effector
phase of EAE.41 Ly6Gþ cells, expanded in preimmune
KitW-sh/W-sh mice, further increased in lymph nodes on
immunization and infiltrated earlier the CNS. We confirmed
in vivo the pathogenetic, rather than immunosuppressive,
nature of these cells in both c-Kit mutated and WT mice, as
both strains showed attenuated and delayed symptoms when
treated with anti-Gr1 mAb. However, the alterations carried
by KitW-sh/W-sh mice in the Ly6Gþ subset were not causally
related to the enhanced EAE clinical course, as granulocyte
depletion could not abate the difference between KitW-sh/W-sh
and Kitþ /þ mice in terms of clinical disease expression,
despite it dramatically reduced encephalitogenic T-cell re-
sponses at the same extent in both groups compared with
untreated controls.
Overall our data tend to exclude a role for peripheral MCs
in regulating T-cell priming, even though we could detect, in
draining lymph nodes of KitW-sh/W-sh mice at d10 on im-
munization, enhanced T-cell proliferation, increased secre-
tion of proinflammatory cytokines and decreased IL-10
amount, partially in line with previous data.21 The frequency
of Th17 and Th1 cells was higher in KitW-sh/W-sh mice at d10
post immunization. Even though the discovery that Th17
cells drove autoimmunity subverted the previous belief that
Th1 cells were the most relevant pathogenic cells in EAE,
it is now well accepted that both T-helper subsets
participates, through distinct mechanisms, to EAE and MS
pathogenesis.61 Indeed, the IL-12-Th1 and the IL23-Th17 axes
lead to prominent macrophage or granulocyte infiltrate,
respectively, in spite of clinically indistinguishable disease
courses.40 Th17 encephalitogenic cells displayed the unique
feature to enter the not-inflamed CNS62 and to promote the
assembly of ectopic lymphoid follicle-like structures in the
CNS.63 The observed increase of Th17 and Th1 cells in
KitW-sh/W-sh mice may be related to the fact that MCs can exert
some influence on T-cell differentiation by releasing a variety
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of cytokines in response to adjuvants on immunization.64 In
the KitW/W-v model, a central role has been attributed to MCs
in promoting T-cell priming, but MCs also enhanced in-
flammation in the effector phase of the disease.18,38 Indeed, on
one side, MC i.v. reconstitution recovered normal EAE, al-
though without repopulating the CNS;18 on the other side,
KitW/W-v mice still developed milder symptoms on passive
transfer of encephalitogenic T cells.38 Others have found that
MCs are attracted from the spleens to the draining lymph
nodes upon immunization.18 The cytokine IL-9, produced by
Th17 cells in the lymph nodes of MOG35–55-primed mice, has
been recently identified to recruit MCs in lymphoid organs
and to promote EAE development and progression.65 We have
shown in vitro that activated MCs inhibit Treg suppression and
promote the differentiation of Th17 effector cells.19
In vivo, MCs colocalized with Th17 cells and Treg in draining
lymph nodes of MOG35–55-immunized mice, thus potentially
engaging multiple interactions with cells participating to
adaptive immune response.19 In this study, we found that
immunization in WT mice induced an increase in MC
infiltration in draining lymph nodes, which was associated
with a preferential distribution of MCs in T-cell perifollicular
areas of the lymph node cortex, and with a certain degree
of MC clustering. By contrast, no significant change in MC
infiltration and distribution was observed in the CNS of WT
mice following immunization, supporting that MC functions
related to Ag stimulation are mainly played in the DLNs.
Analysis of naive and immunized KitW-sh/W-sh mice highlighted
the absence of MCs in steady-state and inflamed tissues,
respectively. Grippingly, the absence of MCs from DLNs of
immunized KitW-sh/W-sh mice was associated with a lower
number of IL-10-expressing cells populating DLNs as com-
pared with that observed in WT mice. This was in favor of a
role for MCs in regulating IL-10 production during immune
response instruction.
A high fraction of degranulated MCs has been detected in
the CNS of MBP-immunized mice.66 In a model of allograft
tolerance, MC degranulation has been shown to break Treg-
mediated immunological tolerance.37 However, by toluidine
blue staining, we could not detect significant MC de-
granulation in draining lymph nodes or in the CNS of
MOG35–55-immunized mice. Accordingly, ultrastructural
analysis of MCs infiltrating the CNS in a marmoset model of
EAE showed selective secretion, rather than degranulation.67
Many data suggest that MCs can engage multiple inter-
actions with Treg.19,26,32 In this study, we found a defect in
Treg frequency in lymphoid organs of KitW-sh/W-sh mice be-
fore and during EAE development, at both acute and chronic
phases. The reasons for impaired Treg homeostasis in naive
KitW-sh/W-sh mice remain presently obscure. Contrary to
another c-Kit mutant, showing severe defects in thymocytes
development,68 we could not detect any major alteration in
thymocyte subsets in KitW-sh/W-sh mice (data not shown).
Notably, BMMC reconstitution restored a physiological
Treg frequency in LN of preimmune KitW-sh/W-sh mice.
This observation points to a Treg-extrinsic role of this c-Kit
mutation in shaping Treg compartment and suggests that
MCs may not only mold Treg plasticity but also support Treg
homeostasis. The OX40–OX40L axis may be involved in a
defective Treg expansion in MC-deficient mice. Indeed, MCs
constitutively express OX40L26 and OX40 is a key signal in
supporting Treg fitness especially under inflammatory con-
ditions.69 Treg are important suppressor cells in both the
initiation and the recovery phase of EAE,70 therefore the
enhanced EAE disease course in KitW-sh/W-sh mice could be
associated to the decreased Treg accumulation in LN and
spleen. However, Kitþ /þ and KitW-sh/W-sh mice showed the
same proportion of CNS-infiltrating Treg and BMMCs-
reconstituted mice still developed exacerbated symptoms
despite the recovery of a physiological Treg frequency.
MCs residing and/or recruited to the CNS has several roles
in non-immunological conditions. KitW-sh/W-sh mice show a
greater anxiety-like phenotype than WT controls.71 Located
in close proximity with the blood–brain barrier, MCs
represent early responders to cerebral ischemia and
potent inflammatory effector cells.72 MCs may even mod-
ulate tumor metastasization into the brain.73 In KitW/W-v,
meningeal MCs promote a breach in the blood–brain barrier
to allow the entry of inflammatory cells.20 Overall these
functions imply a role for MCs in increasing, rather than
regulating, the permeability of blood-brain barrier. On the
contrary, we found here an enhanced immune infiltrate in
MC-deficient KitW-sh/W-sh mice, especially granulocytes. Of
note, we found more granulocytes infiltrating also the CNS of
HDC/ mice, carrying histamine deficiency and MC pau-
city.28 Future experiments will unravel the true role of MCs
in promoting or regulating the access of immune cells to
inflamed CNS.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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